IMUXHealthcare · BiotechnologyThe 13 Wall Street analysts covering Immunic, Inc. hold a median 12-month price target of $30 — +284.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Immunic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (73): Smaller than most of the companies we track.
Value (10): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IMUX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +284.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $45 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 17 Aug 2026 | Wedbush | Initiates | Outperform | — |
| 17 Aug 2026 | Wedbush | Initiates | Outperform | $45 |
| 22 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 22 May 2026 | B. Riley Securities | Maintains | Buy | $40 → $27 |
| 30 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2026 | Stifel | Initiates | Buy | — |
| 15 Apr 2026 | D. Boral Capital | Downgrade | Hold | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Sept 2025 | Chardan Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IMUX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Immunic, Inc. returned −2.3% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 75% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunic, Inc. has a market value of $108.9M and an enterprise value of −$45.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$111.6M.
Free cash flow in the twelve months to 30 June 2026: −$88.0M.
Trailing P/E: −1.3×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Immunic, Inc. employs 100 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Immunic announced it will host a virtual R&D Day focused on progressive multiple sclerosis on November 5, 2026, at 12:30 p.m. ET. Members of the company’s management team will participate.
Why it matters — The event will provide IMUX watchers with a company update focused on its work in progressive multiple sclerosis.
Zacks Investment Research added IMUX to its Zacks Rank #1 (Strong Buy) List on October 22, 2026, alongside BBCP, UCB, TGS and STX.
Why it matters — The listing is a Zacks classification relevant to investors following IMUX.
Immunic announced four poster presentations of new clinical, biomarker and preclinical data on vidofludimus calcium at MSToronto2026. The reported findings included CALLIPER extension disability outcomes and safety, exploratory biomarker analyses, and preclinical neuroprotective effects.
Why it matters — The presentations add data on the investigational therapy’s outcomes, biomarkers and potential mechanisms that IMUX watchers may follow as its development progresses.
Immunic appointed Jaa Roberson as its first Chief People Officer. Roberson will report to CEO Erik Lundgren and join the executive leadership team.
Why it matters — The appointment comes as Immunic prepares for a pivotal multiple sclerosis trial readout expected by the end of 2026.
Immunic appointed Jaa Roberson as chief people officer, effective October 19, 2026. She will report to CEO Erik Lundgren and join the executive leadership team.
Why it matters — The appointment supports Immunic’s stated strategy to build a multiple sclerosis organization ahead of a potential transition to a fully integrated commercial company.
The 13 Wall Street analysts covering Immunic, Inc. have a median 12-month price target of $30, with estimates ranging from $22 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Immunic, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunic, Inc. 26 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Immunic, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +284.9% from the last close, and Ticker Nerd's factor model ranks Immunic, Inc. 26 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Immunic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMUX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $85 over the next 12 months.
Immunic, Inc. returned -2.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026". Immunic announced it will host a virtual R&D Day focused on progressive multiple sclerosis on November 5, 2026, at 12:30 p.m. ET. Members of the company’s management team will participate.
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.
CEO Mr. Erik Lundgren · 100 employees · United States · https://www.imux.com
